Clinical trial • Phase IV • Respiratory

OXYGEN for Weaning failure | Weaning of mechanical ventilation

Phase IV trial of OXYGEN for Weaning failure | Weaning of mechanical ventilation.

Overview

Trial Therapeutic Area
Respiratory
Trial Disease
Weaning failure | Weaning of mechanical ventilation
Trial Stage
Phase IV
Drug Modality
Other

Key dates

Initial CTIS Submission Date
23-07-2024
First CTIS Authorization Date
07-10-2024

Trial design

Non-Invasive Ventilation (NIV) versus High Flow Oxygen therapy (HFOT); no drug dose or schedule specified-controlled Phase IV trial across 8 sites in Spain.

Comparator
Non-Invasive Ventilation (NIV) versus High Flow Oxygen therapy (HFOT); no drug dose or schedule specified
Target Sample Size
260

Eligibility

Recruits 260 No vulnerable populations selected (isVulnerablePopulationSelected: false). Consent/assent handling not specified in available data..

Vulnerable Population
No vulnerable populations selected (isVulnerablePopulationSelected: false). Consent/assent handling not specified in available data.

Inclusion criteria

  • {"criterion_text":"- Age ≥ 65 years\n- Body mass index (BMI)>30\n- Chronic obstructive pulmonary disease (COPD) or asthma as a cause of invasive mechanical ventilation\n- Cardiac failure as a cause of intubation or history of ejection fraction <= 30%\n- Acute Physiology and Chronic Health Evaluation (APACHE II) > 12 at the time of extubation\n- Time of mechanical ventilation > 7 days\n- Positive water balance\n- Difficult or prolonged weaning\n- Pneumonia (or any medical pathology over surgical) as a cause of ARF\n- Hypercapnia (paCO2 > 45 mmHg) at the time of extubation\n- Ineffective cough\n- Abundant secretions"}

Exclusion criteria

  • {"criterion_text":"- Structural neurologic disease\n- Not intubation order\n- Life support therapy limitation\n- Tracheotomized\n- Spinal cord injury\n- Scheduled surgical intervention in the next 48 hours post-extubation\n- Re-admission\n- Transfer to another center\n- Refusal of the patient or relatives\n- Direct extubation without performing a spontaneous breathing trial\n- Contraindication to apply NIV or high flow oxygen"}

Endpoints

Primary endpoints

  • {"endpoint_text":"- Acute respiratory failure within 48 hours after extubation","definition_or_measurement_approach":""}

Secondary endpoints

  • {"endpoint_text":"- Intubation\n- Nosocomial infection\n- Tracheotomy\n- Organ failure\n- ICU Mortality\n- Hospital mortality\n- 28-day mortality\n- ICU length of stay\n- Hospital length of stay\n- Duration of mechanical ventilation","definition_or_measurement_approach":""}

Recruitment

Planned Sample Size
260
Recruitment Window Months
36
Consent Approach
Informed consent required; subject information and informed consent form available (document L1_HIP_General_v1). No details on assent, age-specific documents, or languages specified in the available data.

Geography

Total Number Of Sites
8
Total Number Of Participants
260

Spain

Earliest CTIS Part Ii Submission Date
05-06-2024
Latest Decision Or Authorization Date
14-01-2025
Processing Time Days
223
Number Of Sites
8
Number Of Participants
260

Sites

Site Name
Hospital De Tortosa Verge De La Cinta
Department Name
Intensive Care Unit
Principal Investigator Name
Pablo Concha Martínez
Principal Investigator Email
pconcha.ebre.ics@gencat.cat
Contact Person Name
Pablo Concha Martínez
Contact Person Email
pconcha.ebre.ics@gencat.cat
Site Name
Hospital De Manises
Department Name
Intensive Care Unit
Principal Investigator Name
Juan Antonio Fernandez Cabrera
Principal Investigator Email
juanantoniofernandezcabrera@gmail.com
Contact Person Name
Juan Antonio Fernandez Cabrera
Site Name
Hospital Francesc De Borja De Gandía
Department Name
Intensive Care Unit
Principal Investigator Name
Susana Isabel Gil García
Principal Investigator Email
gil_susgar@gva.es
Contact Person Name
Susana Isabel Gil García
Contact Person Email
gil_susgar@gva.es
Site Name
Consorcio Hospitalario Provincial De Castellon
Department Name
Intensive Care Unit
Principal Investigator Name
Manuel Cubedo Bort
Principal Investigator Email
cubedomanuel@gmail.com
Contact Person Name
Manuel Cubedo Bort
Contact Person Email
cubedomanuel@gmail.com
Site Name
Hospital De Sagunto
Department Name
Intensive Care Unit
Principal Investigator Name
Adrian Quinza Real
Principal Investigator Email
quinza_jos@gva.es
Contact Person Name
Adrian Quinza Real
Contact Person Email
quinza_jos@gva.es
Site Name
Hospital Arnau De Vilanova De Valencia
Department Name
Intensive Care Unit
Principal Investigator Name
Amparo Navarro Eduardo
Principal Investigator Email
amparonavarroeduardo@gmail.com
Contact Person Name
Amparo Navarro Eduardo
Contact Person Email
amparonavarroeduardo@gmail.com
Site Name
Hospital General Universitario De Castellon
Department Name
Intensive Care Unit
Principal Investigator Name
Francisco Bernal Julian
Principal Investigator Email
bernaljulianpaco@gmail.com
Contact Person Name
Francisco Bernal Julian
Contact Person Email
bernaljulianpaco@gmail.com
Site Name
Hospital Universitario Dr Peset Aleixandre
Department Name
Intensive Care Unit
Principal Investigator Name
Alberto Belenguer Muncharaz
Principal Investigator Email
belengueralberto8@gmail.com
Contact Person Name
Alberto Belenguer Muncharaz
Contact Person Email
belengueralberto8@gmail.com

Sponsor

Primary sponsor

Full Name
Fundacion Para El Fomento De La Investigacion Sanitaria Y Biomedica De La Comunitat Valenciana
Organisation Type
Patient organisation/association
Country Of Registered Address
Spain

Third parties

  • {"country":"","full_name":"Fundacion FISABIO","duties_or_roles":"Source of monetary support","organisation_type":""}
  • {"country":"","full_name":"Hospital Universitario Doctor Peset","duties_or_roles":"Source of monetary support","organisation_type":""}
  • {"country":"Spain","full_name":"AIR LIQUIDE SANTE INTERNATIONAL","duties_or_roles":"Product manufacturer / marketing authorisation holder for investigational product","organisation_type":""}

Investigational products

Investigational Product Name
Oxígeno Medicinal Líquido Air Liquide 99,5% v/v, gas criogénico medicinal en recipientes fijos.
Active Substance
OXYGEN
Modality
Other
Routes Of Administration
INHALATION GAS
Route
INHALATION GAS
Authorisation Status
Marketing authorised (marketingAuthNumber: 66974)
Maximum Dose
100 percent

Related trials

Other published trials that may interest you.